Metabolic syndrome worsens elderly depression
In elderly adults with depression, the presence of metabolic syndrome (MetS) appears to increase symptom severity and disorder chronicity, a recent study has found.
In 435 elderly adults receiving an open-label, protocolized extended-release venlafaxine treatment, the unadjusted model showed a significantly longer time to remission in participants with baseline MetS (n=222) than in those without (n=211; hazard ratio [HR], 0.71; 95 percent CI; 0.52–0.95; p=0.02).
After adjusting for potential confounders, such as gender and depressive episodes, the significant relationships (HR, 0.86; 0.64–1.16) were attenuated
In terms of individual metabolic variables, a higher diastolic blood pressure (DBP; HR, 0.88 per 10 mm Hg increase; 0.77–0.995) and the presence of more MetS components (HR, 0.89 per additional component; 0.80–0.99) were associated with shorter time to remission, according to a univariate regression model.
In contrast, elevated high-density lipoprotein cholesterol (HDL-C) levels predicted shorter time to remission (HR, 1.11 per 10 mg/dL increase; 1.02–1.21). Only DBP remained significantly predictive in the adjusted model (HR, 0.87 per 10 mm Hg increase; 0.77–0.99).
A history of smoking (p=0.81), cerebrovascular disease (p=0.95) and cardiovascular disease (p=0.95), insulin levels (p=0.88), HDL-C (p=0.46), and total cholesterol (p=0.79) had no significant effects on the time to remission.
Finally, the use of medications for glucose, lipids and blood pressure, such as coprescribed beta-blockers or antihypertensives, did not significantly change the relationships between the metabolic and atherosclerotic variables and time to remission.